Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) stock plunged more than 22% in the premarketing today after the news that, since obtaining a subpoena from IIROC Company needs to clarify that it’s management and Board of Directors are unsure of any radical change in the company’s activities that will account for the sudden uptick in market activity.
The company has a monthly performance of 87.40%, compared to its half year performance of -28.09%. The biotech firm has 32 employees on its payroll and a Market capitalization of 41.66M. The price of the stock was trading -25.16% away from its 200-day simple moving average.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored